About 10,750 results

ALLMedicine™ Alzheimer Disease Center

Research & Reviews  3,948 results

The case for low-level BACE1 inhibition for the prevention of Alzheimer disease.
https://doi.org/10.1038/s41582-021-00545-1 10.15252/emmm.201606210 10.1016/j.cell.2015.12.056 10.1006/mcne.1999.0811 10.1038/990114 10.1126/science.286.5440.735 10.1038/990107 10.1007/s40263-019-00613-7 10.1056/NEJMoa1812840 10.1056/NEJMc1813435 10.1056/NEJMe1903193 10.1056/NEJMoa1210951 10.1001/archneurol.2012.2194 10.1016/j.cell.2014.10.016 10.1084/jem.20202560 10.1002/alz.041140 10.1016/j.phrs.2018.02.014 10.3233/JAD-150834 10.1126/scitranslmed.aad9704 10.15252/emmm.201809316 10.1056/NEJMoa1706441 10.1001/jamaneurol.2019.3988 10.1056/NEJMoa2100708 10.1093/eurheartj/ehx566 10.1038/ncomms13042 10.1002/emmm.201101084 10.1016/j.cmet.2011.06.018 10.1074/jbc.M112.444703 10.26508/lsa.201800026 10.1073/pnas.160115697 10.1074/jbc.M105583200 10.1073/pnas.1220748110 10.1038/srep21917 10.1038/emboj.2012.173 10.1074/jbc.M112.377465 10.1371/journal.pone.0008477 10.15252/embj.2020105693 10.1186/s13195-019-0520-1 10.1016/j.trci.2019.02.005 10.1001/jamaneurol.2020.4857 10.1002/alz.12164 10.1186/s13195-018-0415-6 10.1016/j.jalz.2018.06.3053 10.1002/alz.041142 10.1093/brain/awaa332 10.1074/jbc.M611687200 10.1038/srep00231 10.1074/jbc.M505249200 10.1523/JNEUROSCI.2766-05.2005 10.1084/jem.20171831 10.1038/s41598-019-56329-7 10.1016/j.celrep.2015.07.059 10.1038/nature11283 10.1002/ana.24969 10.1074/jbc.M114.589069 10.1186/1750-1326-7-39 10.1016/j.jalz.2018.02.018 10.1038/nature19323 10.1016/j.neurol.2013.07.017 10.3233/JAD-2011-0059 10.1126/scitranslmed.3007941 10.1002/alz.041139 10.1002/alz.041143 10.1523/JNEUROSCI.4560-08.2009 10.1038/s41593-020-00737-w 10.1016/j.jalz.2016.06.2365 10.1016/j.atherosclerosissup.2004.08.007 10.1016/j.neuron.2011.01.002 10.1016/j.trci.2019.05.008 10.1016/j.neuron.2020.09.029 10.1038/s41582-018-0116-6 10.1001/jamaneurol.2014.803 10.1136/jnnp-2015-312383 10.1097/00002093-199700112-00003 10.1016/j.jalz.2016.06.828 10.1016/j.bmcl.2018.12.049 10.1016/j.jalz.2018.06.1353 10.1016/j.semcdb.2020.03.005 10.1016/j.semcdb.2020.05.019 10.15252/embj.201899456 10.1523/JNEUROSCI.5221-09.2010 10.1038/emboj.2010.167 10.1073/pnas.96.7.3922 10.1038/nature14864 10.1038/ncomms9762 10.1016/j.pneurobio.2015.10.003 10.1126/scitranslmed.aao5620 10.1038/emboj.2013.146 10.1523/JNEUROSCI.3372-12.2013 10.1126/science.1132341 10.1038/nn1797 10.1016/j.celrep.2013.06.005 10.1016/j.biopsych.2016.12.023 10.1186/s13024-016-0134-z 10.1074/jbc.M112.415505 10.15252/embj.201798858 10.1073/pnas.1716322115
Nature Reviews. Neurology; McDade E, Voytyuk I et. al.

Sep 23rd, 2021 - Alzheimer disease (AD) is the most common cause of dementia in older individuals (>65 years) and has a long presymptomatic phase. Preventive therapies for AD are not yet available, and potential disease-modifying therapies targeting amyloid-β plaq...

Diet enriched in omega-3 fatty acids alleviates olfactory system deficits in APOE4 tran...
The European Journal of Neuroscience; Lessard-Beaudoin M, M Gonzales L et. al.

Sep 23rd, 2021 - Olfactory dysfunction is observed in several neurological disorders including Mild Cognitive Impairment (MCI) and Alzheimer disease (AD). These deficits occur early and correlate with global cognitive performance, depression and degeneration of ol...

Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease.
JAMA Neurology; Janelidze S, Teunissen CE et. al.

Sep 21st, 2021 - Blood-based tests for brain amyloid-β (Aβ) pathology are needed for widespread implementation of Alzheimer disease (AD) biomarkers in clinical care and to facilitate patient screening and monitoring of treatment responses in clinical trials. To co...

Can we learn lessons from the FDA's approval of aducanumab?
https://doi.org/10.1038/s41582-021-00557-x 10.1155/2014/908915 10.1016/j.jalz.2011.10.007 10.1126/science.1072994 10.1038/s41582-019-0295-9 10.1002/alz.12213 10.1016/S1474-4422(19)30480-6 10.1001/jama.2021.3854 10.1016/S2215-0366(21)00197-8 10.1136/bmj.n1503 10.1038/nature19323 10.1016/j.trci.2016.06.002 10.1016/j.jalz.2011.05.2351 10.1056/NEJMoa1304839 10.1038/s41591-021-01369-8 10.1056/NEJMoa1705971 10.1038/s41582-018-0116-6 10.1186/s13195-021-00838-z 10.1001/jamainternmed.2021.4607 10.1016/j.trci.2019.06.005 10.1212/WNL.0000000000012022 10.1080/00031305.2016.1154108 10.1136/bmj.n156 10.1056/NEJMoa2100708 10.1186/s13195-021-00813-8 10.1097/WAD.0b013e31821300bc 10.1016/j.jalz.2015.02.004 10.2967/jnumed.114.148981 10.2967/jnumed.116.188029 10.1038/d41586-021-01546-2 10.1001/jama.2017.9415 10.1186/s12916-019-1344-3 10.1002/alz.12444 10.1016/j.nicl.2013.02.006 10.1186/s13195-016-0220-z 10.1212/WNL.0b013e3181b23564 10.1016/S1474-4422(21)00066-1 10.1093/oxrep/grj013 10.1056/NEJMhle1710706 10.1172/JCI200317527 10.1186/s12916-017-0902-9 10.1016/j.eclinm.2020.100332 10.1001/jamainternmed.2019.0462 10.1200/JCO.2014.57.8740 10.1016/j.eclinm.2020.100269 10.1001/jamainternmed.2020.8441 10.1111/1468-0009.12403
Nature Reviews. Neurology; Liu KY, Howard R

Sep 19th, 2021 - On 7 June 2021, aducanumab was granted accelerated approval for the treatment of Alzheimer disease (AD) by the FDA on the basis of amyloid-lowering effects considered reasonably likely to confer clinical benefit. This decision makes aducanumab the...

A Novel Selective PKR Inhibitor Restores Cognitive Deficits and Neurodegeneration in Al...
The Journal of Pharmacology and Experimental Therapeutics; Lopez-Grancha M, Bernardelli P et. al.

Sep 18th, 2021 - In Alzheimer disease (AD), the double-strand RNA-dependent kinase protein kinase R (PKR )/EIF2AK2 is activated in brain with increased phosphorylation of its substrate eukaryotic initiation factor 2α (eIF2α). AD risk-promoting factors, such as Apo...

see more →

Guidelines  6 results

ACR Appropriateness Criteria® Dementia.
Journal of the American College of Radiology : JACR; , Moonis G et. al.

May 7th, 2020 - Degenerative disease of the central nervous system is a growing public health concern. The primary role of neuroimaging in the workup of patients with probable or possible Alzheimer disease has typically been to exclude other significant intracran...

Falls Risk and Alzheimer Disease: A Patient Guide.
Archives of Physical Medicine and Rehabilitation; Kahya M, Sood P et. al.

Mar 3rd, 2020 - Falls Risk and Alzheimer Disease: A Patient Guide.|2020|Kahya M,Sood P,Devos H,Krishnan S,Hirsch MA,|

Diagnostic criteria for vascular cognitive disorders: a VASCOG statement.
Alzheimer Disease and Associated Disorders; Sachdev P, Kalaria R et. al.

Mar 19th, 2014 - Several sets of diagnostic criteria have been published for vascular dementia since the 1960s. The continuing ambiguity in vascular dementia definition warrants a critical reexamination. Participants at a special symposium of the International Soc...

Update on appropriate use criteria for amyloid PET imaging: dementia experts, mild cogn...
Alzheimer's & Dementia : the Journal of the Alzheimer's A... Johnson KA, Minoshima S et. al.

Jul 3rd, 2013 - Amyloid PET imaging is a novel diagnostic test that can detect in living humans one of the two defining pathologic lesions of Alzheimer disease, amyloid-β deposition in the brain. The Amyloid Imaging Task Force of the Alzheimer's Association and S...

Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the ...
Genetics in Medicine : Official Journal of the American C... Goldman JS, Hahn SE et. al.

May 18th, 2011 - Alzheimer disease is the most common cause of dementia. It occurs worldwide and affects all ethnic groups. The incidence of Alzheimer disease is increasing due, in part, to increased life expectancy and the aging baby boomer generation. The averag...

see more →

Drugs  5 results see all →

News  341 results

Mild Cognitive Impairment with Lewy Bodies or Alzheimer’s Disease and Risk of Progression to Dementia

Apr 26th, 2021 - Takeaway Patients with mild cognitive impairment (MCI) and clinical characteristics of dementia with Lewy bodies (DLB) had a worse prognosis than MCI-Alzheimer’s disease (MCI-AD), with an increased annual risk of transition from MCI to dementia. M...

TDP-43 Protein Declines Years Before Death in Alzheimer's

Nov 9th, 2020 - Brain levels of TAR DNA binding protein 43 (TDP-43), a key factor in the neurodegeneration that occurs with Alzheimer's disease, begin declining nearly two decades prior to the end of life and show an independent effect on the rate of hippocampal ...

Fast Five Quiz: Alzheimer Disease Management

Aug 19th, 2020 - Alzheimer disease is a chronic, neurodegenerative disorder of the aging population that results in progressive cognitive and behavioral dysfunction. Afflicting more than 6 million Americans and more than 8 million Europeans, Alzheimer disease is t...

Fast Five Quiz: Alzheimer Disease Management

Aug 19th, 2020 - Alzheimer disease is a chronic, neurodegenerative disorder of the aging population that results in progressive cognitive and behavioral dysfunction. Afflicting more than 6 million Americans and more than 8 million Europeans, Alzheimer disease is t...

Fast Five Quiz: Alzheimer Disease Management

Aug 19th, 2020 - Answer 2/5 Which of the following has been shown to achieve the highest levels of cognitive and functional abilities in patients with Alzheimer disease? Your peers chose: Early diagnosis and treatment 0% Antidepressants 0% Loop diuretics and CCBs ...

see more →